The first four weeks are not about weight loss. They are about installing the appetite signal without wrecking your lean mass on the way down. Every pound lost on a GLP-1 monotherapy is roughly 30-40% lean tissue — muscle, organ, bone density — unless you scaffold the protocol from day one. Phase 1 is where that scaffolding gets bolted in. Miss it and you spend Phase 2 trying to rebuild what you already lost.
What's actually happening in the first 28 days
GLP-1 receptor agonists work through three converging mechanisms: delayed gastric emptying, central appetite suppression via the hypothalamic arcuate nucleus, and direct activation of the area postrema — the chemosensory trigger zone sitting outside the blood-brain barrier. That last one is why nausea is the dose-limiting toxicity. The area postrema is more porous than the rest of the BBB, so circulating GLP-1 agonists can directly fire the vomiting reflex when receptor occupancy spikes too fast.
The substrate is unambiguous on this: dose-escalation pacing, not absolute dose, predicts tolerability. Phase 1 and Phase 3 trials of incretin mimetics show that aggressive titration without ramp-up produces nausea/vomiting rates 2-3x higher at the same steady-state dose. The drug isn't the problem. The slope is.
Meanwhile, the muscle problem starts in week one. Caloric deficit alone drives proteolysis through the ubiquitin-proteasome and SMAD2/3 pathways. GLP-1 agonists amplify this because reduced food intake reduces leucine availability, mTOR signaling drops, and myofibrillar protein synthesis falls below breakdown. Testosterone, which normally inhibits myostatin signaling, also drops in caloric deficit — so myostatin-driven atrophy accelerates. By Week 4 of unsupported GLP-1 use, lean body mass loss is already measurable on DXA.
The Phase 1 stack solves both problems simultaneously: slow GLP-1 titration to keep nausea below the quit-threshold, and a muscle-protective scaffold of resistance training, leucine-loaded protein intake, and a growth-axis peptide that keeps mTOR alive in a hypocaloric environment.
The Phase 1 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Semaglutide | 0.25 mg → 0.5 mg | SubQ (abdomen, thigh, or upper arm) | 1x/week, same day | 🔵 Clinical | Start 0.25 mg Weeks 1-4. Titrate to 0.5 mg only if nausea ≤ Grade 1. Do NOT push to 1.0 mg in Phase 1. |
| Tirzepatide (alternative to Semaglutide) | 2.5 mg | SubQ | 1x/week | 🔵 Clinical | Hold at 2.5 mg for full 4 weeks. Substrate is explicit: tolerance acquired here predicts adherence at higher doses. |
| CJC-1295 (no DAC) + Ipamorelin | 100 mcg CJC + 200 mcg Ipamorelin | SubQ (rotate sites) | 5 nights/week, pre-bed, fasted | 🟢 Expert | Pulsatile GH release → preserves IGF-1, defends lean mass during caloric deficit. Pre-bed timing piggybacks on natural GH pulse. |
| BPC-157 | 250 mcg | SubQ (abdomen, near tissue of concern) | 2x/day | 🟢 Expert | Gut-protective during GI side effect window. Substrate consistently cites mucosal repair benefit during GLP-1 ramp. |
| Leucine-loaded protein | 1.6-2.2 g/kg lean body mass | Oral | Distributed across 3-4 feedings | 🔵 Clinical | Non-negotiable. Each feeding must hit ≥3 g leucine to cross the mTOR threshold. Whey isolate post-training. |
| Resistance training | 3-4 sessions, compound-heavy | — | Weekly | 🔵 Clinical | Mechanical tension is the only signal that overrides the catabolic environment. Substrate is firm: synergistic with protein intake on myofibrillar synthesis biomarkers. |
Titration logic — why 0.25 mg for four weeks
The substrate framing is that the starting dose of Semaglutide is sub-therapeutic for weight loss. That's the point. Weeks 1-4 are receptor acclimatization, not intervention. Pushing to 0.5 mg before Week 5 — or skipping the 0.25 mg phase entirely — is the single most common reason protocols fail at Week 6 from intolerable nausea and patient dropout.
Tirzepatide users get the same rule at 2.5 mg. The dual GIP/GLP-1 agonism produces faster gastric-emptying delay than pure GLP-1, so the area postrema signal is more aggressive. Hold the starting dose. Let the receptors downregulate. Then climb.
Nausea management during titration
The substrate-supported playbook:
- Inject in the evening of a low-eating day (e.g. Sunday evening before a light Monday). Peak plasma occurs 24-48 hours post-injection — you want that window to land when food intake is naturally low.
- Eat small, eat early. Gastric emptying is delayed 30-70%. Large boluses sit and ferment. Three small protein-forward feedings beat two large ones.
- Avoid high-fat triggers in Weeks 1-2. Fat further delays emptying. Add it back Week 3 once tolerance shows.
- BPC-157 twice daily. The substrate is consistent that BPC-157 mitigates the upper-GI distress that drives early dropout — mucosal protection, motility normalization.
If nausea exceeds Grade 1 (interferes with daily activity), do not advance the dose. Hold. The titration calendar is a guideline, not a deadline.
What you should feel
- Week 1: Appetite reduction is subtle. Food noise drops first — the constant background thought of "what's next to eat" goes quiet. Mild nausea 24-48 hours post-injection is expected.
- Week 2: Portion size naturally halves. Sweet cravings dull. First weight changes are mostly water (glycogen depletion as carb intake falls). Don't celebrate it.
- Week 3: Energy stabilizes if protein and training are dialed in. Sleep quality often improves from the CJC/Ipamorelin pulse. Strength in the gym holds — this is the early signal that the muscle scaffolding is working.
- Week 4: True fat loss begins to register. Expect 1-2% body weight reduction by Day 28. Lean mass should hold within 1% of baseline if the stack is executed.
What's NOT happening yet
- Significant fat loss. Most weight in Weeks 1-2 is water and gut content. Real adipose loss starts Week 3-4 and accelerates in Phase 2.
- Metabolic remodeling. Insulin sensitivity improves measurably, but the deeper mitochondrial work — fat oxidation capacity, MOTS-c activation — is a Phase 2 target. Don't add 5-Amino-1MQ or MOTS-c yet. One variable at a time.
- Aggressive caloric restriction. Do not stack a hard deficit on top of titration. Let the drug suppress appetite naturally. The substrate is clear: stacking voluntary restriction on pharmacologic restriction is what produces the lean mass collapse and rebound metabolism.
- Maximum dose efficacy. 0.25 mg Semaglutide and 2.5 mg Tirzepatide are titration doses, not therapeutic doses. The full appetite suppression effect arrives in Phase 2 when you climb to 0.5-1.0 mg (Sema) or 5.0 mg (Tirz). Phase 1 is the runway, not the takeoff.
- Visible body recomposition. Mirror changes lag scale changes by 3-4 weeks. Photo on Day 1, photo on Day 28. The scale will move first; the silhouette catches up in Phase 2.
The single non-negotiable from this chapter: the muscle scaffolding is not optional. Protein intake, resistance training, and the GH-axis pulse run from Day 1 alongside the GLP-1 — not after. Every protocol that delays the scaffolding loses lean mass that no Phase 2 stack can fully recover.
The practitioner corpus describes this titration pace as the difference between protocols that finish at Week 10 and protocols that quit at Week 6. Track your nausea daily, weigh weekly, lift heavy, eat the protein. Adjust.